JP2022058443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022058443A5 JP2022058443A5 JP2021213603A JP2021213603A JP2022058443A5 JP 2022058443 A5 JP2022058443 A5 JP 2022058443A5 JP 2021213603 A JP2021213603 A JP 2021213603A JP 2021213603 A JP2021213603 A JP 2021213603A JP 2022058443 A5 JP2022058443 A5 JP 2022058443A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- sample
- biomarker
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 36
- 239000000090 biomarker Substances 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 35
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 21
- 150000003839 salts Chemical group 0.000 claims 5
- 239000007787 solid Chemical group 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- IXZOHGPZAQLIBH-NRFANRHFSA-N (3s)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N([C@@H]2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-NRFANRHFSA-N 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 210000000265 leukocyte Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000005259 peripheral blood Anatomy 0.000 claims 4
- 239000011886 peripheral blood Substances 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- VVHQVXXPZDALDV-BOXHHOBZSA-N (3s)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione;hydrochloride Chemical compound Cl.O=C1N([C@@H]2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 VVHQVXXPZDALDV-BOXHHOBZSA-N 0.000 claims 3
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 claims 3
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102000015367 CRBN Human genes 0.000 claims 2
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 claims 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 2
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 210000003714 granulocyte Anatomy 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010013082 Discomfort Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000000616 Hemoptysis Diseases 0.000 claims 1
- 208000004044 Hypesthesia Diseases 0.000 claims 1
- 108010013958 Ikaros Transcription Factor Proteins 0.000 claims 1
- 102000017182 Ikaros Transcription Factor Human genes 0.000 claims 1
- 206010023232 Joint swelling Diseases 0.000 claims 1
- 208000008771 Lymphadenopathy Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010031009 Oral pain Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010034719 Personality change Diseases 0.000 claims 1
- 206010034972 Photosensitivity reaction Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000009266 disease activity Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000034783 hypoesthesia Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000018555 lymphatic system disease Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 231100000862 numbness Toxicity 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462000428P | 2014-05-19 | 2014-05-19 | |
| US62/000,428 | 2014-05-19 | ||
| US201462053626P | 2014-09-22 | 2014-09-22 | |
| US62/053,626 | 2014-09-22 | ||
| JP2020080644A JP2020143083A (ja) | 2014-05-19 | 2020-04-30 | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020080644A Division JP2020143083A (ja) | 2014-05-19 | 2020-04-30 | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022058443A JP2022058443A (ja) | 2022-04-12 |
| JP2022058443A5 true JP2022058443A5 (https=) | 2022-09-07 |
Family
ID=53268937
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568653A Pending JP2017522270A (ja) | 2014-05-19 | 2015-05-18 | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
| JP2020080644A Pending JP2020143083A (ja) | 2014-05-19 | 2020-04-30 | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
| JP2021213603A Pending JP2022058443A (ja) | 2014-05-19 | 2021-12-28 | 全身性エリテマトーデスの治療のための３－（４－（（４－（モルホリノメチル－ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568653A Pending JP2017522270A (ja) | 2014-05-19 | 2015-05-18 | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
| JP2020080644A Pending JP2020143083A (ja) | 2014-05-19 | 2020-04-30 | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US10245266B2 (https=) |
| EP (1) | EP3145513B1 (https=) |
| JP (3) | JP2017522270A (https=) |
| ES (1) | ES2969532T3 (https=) |
| TW (2) | TWI745271B (https=) |
| WO (1) | WO2015179276A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| NZ727295A (en) | 2012-08-09 | 2018-06-29 | Celgene Corp | Treatment of immune-related and inflammatory diseases |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| US10245266B2 (en) | 2014-05-19 | 2019-04-02 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
| WO2018010142A1 (en) * | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
| AU2019351811B2 (en) | 2018-10-01 | 2025-01-02 | Celgene Corporation | Combination therapy for the treatment of cancer |
| AR123650A1 (es) * | 2020-10-02 | 2022-12-28 | Celgene Corp | Métodos para el tratamiento del lupus eritematoso sistémico y el uso de biomarcadores como un predictor de sensibilidad clínica a terapias |
| WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| EP1064277B1 (en) | 1998-03-16 | 2005-06-15 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| GB0120441D0 (en) | 2001-08-22 | 2001-10-17 | Novartis Forschungsstiftung | Model of autoimmune disease and methods for identifying anti autoimmune disease disorders |
| US7173032B2 (en) | 2001-09-21 | 2007-02-06 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
| AU2007249805B2 (en) | 2006-05-12 | 2013-01-10 | University Of Miami | Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma |
| US20080045485A1 (en) | 2006-08-17 | 2008-02-21 | Peter Muir | Methods of diagnosing synovial disease in a mammal by detecting bacterial DNA in synovial tissues from dogs with inflammatory knee arthritis and degenerative anterior cruciate ligament rupture |
| SG177221A1 (en) | 2006-12-15 | 2012-01-30 | Abbott Lab | Novel oxadiazole compounds |
| KR101791757B1 (ko) | 2007-03-20 | 2017-10-30 | 셀진 코포레이션 | 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법 |
| WO2008119170A1 (en) | 2007-03-30 | 2008-10-09 | Chu Sainte Justine | Method of determining risk of scoliosis |
| JP5442185B2 (ja) | 2007-04-24 | 2014-03-12 | 日本メナード化粧品株式会社 | 感作性物質評価方法 |
| WO2009124064A1 (en) | 2008-03-31 | 2009-10-08 | Boston Medical Center Corporation | Predictive marker for topoisomerase i inhibitors |
| EP2274617A4 (en) | 2008-04-10 | 2011-11-09 | Massachusetts Inst Technology | METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS |
| WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
| HUE029289T2 (en) | 2008-12-05 | 2017-02-28 | Abbvie Inc | Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases |
| KR101787768B1 (ko) | 2009-04-18 | 2017-10-18 | 제넨테크, 인크. | 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 |
| EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| TWI509247B (zh) * | 2010-03-12 | 2015-11-21 | 西建公司 | 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記 |
| JP2013540995A (ja) | 2010-08-18 | 2013-11-07 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． | 疾患に対する循環バイオマーカー |
| WO2012115885A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| US9730941B2 (en) * | 2012-06-07 | 2017-08-15 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
| ES2872967T3 (es) * | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| US9371568B2 (en) * | 2012-07-31 | 2016-06-21 | Novartis Ag | Markers associated with human double minute 2 inhibitors |
| NZ727295A (en) * | 2012-08-09 | 2018-06-29 | Celgene Corp | Treatment of immune-related and inflammatory diseases |
| US20140343058A1 (en) | 2012-08-09 | 2014-11-20 | Celgene Corporation | Treatment of systemic lupus erythematosus |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| UA117141C2 (uk) * | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| US10245266B2 (en) * | 2014-05-19 | 2019-04-02 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
-
2015
- 2015-05-18 US US15/312,450 patent/US10245266B2/en active Active
- 2015-05-18 WO PCT/US2015/031345 patent/WO2015179276A1/en not_active Ceased
- 2015-05-18 JP JP2016568653A patent/JP2017522270A/ja active Pending
- 2015-05-18 TW TW104115791A patent/TWI745271B/zh active
- 2015-05-18 EP EP15725213.1A patent/EP3145513B1/en active Active
- 2015-05-18 TW TW110125851A patent/TWI794885B/zh active
- 2015-05-18 ES ES15725213T patent/ES2969532T3/es active Active
-
2019
- 2019-03-01 US US16/290,493 patent/US10596179B2/en active Active
-
2020
- 2020-02-25 US US16/801,000 patent/US10980812B2/en active Active
- 2020-04-30 JP JP2020080644A patent/JP2020143083A/ja active Pending
-
2021
- 2021-03-29 US US17/216,106 patent/US11660302B2/en active Active
- 2021-12-28 JP JP2021213603A patent/JP2022058443A/ja active Pending
-
2023
- 2023-05-03 US US18/142,973 patent/US20240041894A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022058443A5 (https=) | ||
| JP2020143083A5 (https=) | ||
| Fessel | Renal outcomes of gout and hyperuricemia | |
| JP2017522270A5 (https=) | ||
| Marshall et al. | Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study | |
| RU2012147597A (ru) | Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания | |
| TWI794885B (zh) | 全身紅斑性狼瘡之治療 | |
| AU2018331267B2 (en) | Improved treatment of atopic dermatitis with tradipitant | |
| Kümmerle‐Deschner et al. | Risk factors for severe Muckle‐Wells syndrome | |
| KR20220011652A (ko) | 브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법 | |
| Lee et al. | Comparison of age of onset and frequency of diabetic complications in the very elderly patients with type 2 diabetes | |
| US10934593B2 (en) | Compositions and methods for predicting response and resistance to CDK4/6 inhibition | |
| RU2424806C1 (ru) | Способ определения эффективности лечения рака тела матки | |
| US20220409585A1 (en) | Treatment of autoinflammatory disorders | |
| Souto et al. | CD1a+ dendritic cells in oral lichen planus and amalgam lichenoid reaction | |
| RU2429487C1 (ru) | Способ ранней диагностики поражения почек у больных ревматоидным артритом | |
| CN118434423A (zh) | 用于治疗舍格伦综合征或混合性结缔组织病的tlr7/8拮抗剂 | |
| Williams et al. | Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients | |
| US20220218671A1 (en) | Telmisartan for the treatment of chronic kidney disease in dogs | |
| RU2778614C1 (ru) | Способ прогнозирования развития рецидива при медикаментозном лечении болезни Грейвса | |
| Ferrari et al. | Engineering for Biomedical Sector: A Cross-Industry Approach for the Analysis of Molecular Patterns behind Endothelial Damage Related to Leukemia Therapy | |
| US20260007640A1 (en) | Compositions for the treatment of inflammatory disorders | |
| Thacker | Eosinophilia-myalgia syndrome: the Cleveland Clinic experience | |
| Takahashi et al. | WCN26-4915 Aged kidney exhibits exacerbated tubular injury and decreased interstitial fibrosis after ischemia | |
| Zeitler | Will the Real Creatinine Please Stand Up? Elevated Creatinine in a Patient with Smoldering Myeloma: PO1906 |